This study aims to observe inflammatory biomarkers and their trend over the history of the disease in patients suffering from MPN Ph negative; it also wants to identify any correlations between the aforementioned biomarkers and disease outcomes, considering first of all the occurrence of thrombo-haemorrhagic events and the evolution in the accelerated / blast phase of the disease, shedding light on new tools that can potentially guarantee a prompt and better risk stratification
Age ≥ 18 years at the time of diagnosis of MPN Ph negative
Diagnosis of PV, ET, PMF or post PV and post ET MF, according to current WHO or IWG-MRT criteria (diagnosis since 2000)
Obtaining informed consent
Life expectancy of less than 6 months
Accelerated phase myelofibrosis or MPN with signs of leukemic evolution
Adults diagnosed with PV, ET, PMF or post PV and post ET MF, according to current WHO or IWG-MRT criteria (diagnosis since 2000)
Cohort
Other
Not listed
CBC with leukocyte formula and calculation of the NLR and PLR ratio
Occurrence of arterial and venous thrombotic events
type of event, time to event after diagnosis, during illness
Measurement of new and conventional inflammatory biomarkers
at the occurrence of the transformation in the overt phase from pre-fibrotic phase in the setting of myelofibrosis or at the occurrence of the evolution of the MPN Ph negative disease in an accelerated and / or leukemic phase or after 6 months from the introduction of conventional cytoreduction or target-therapy ( JAk2 inhibitors) or 6 months after the introduction of inflammatory drugs (iron chelators)
Time to thrombo-haemorrhagic events
Time to death and been alive at the end of the study
Time to evolution of the PH negative MPN disease into the fibrotic, accelerated or leukemic phase
Click on the lead sponsor to view all of their trials.
